Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill

Xue Liu; Wenjing Ning; Lei Wang; Han Liu; Hongye Zeng; Xiaojing Qin; Yuanzhi Chen; Fentian Chen; Lin Xu; Yang Zhao; Xiaoqing Chen; Jixian Tang; Yunlong Ren; Xiaowen Yan; Wenxin Luo; Ningshao Xia

doi:10.1002/cac2.12616

PDF

Cancer Communications ›› 2024, Vol. 44 ›› Issue (12) : 1444-1448. DOI: 10.1002/cac2.12616

LETTER TO THE JOURNAL

Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill

Xue Liu¹^,², ,
Wenjing Ning¹^,², ,
Lei Wang³, ,
Han Liu¹^,² ,
Hongye Zeng¹^,² ,
Xiaojing Qin¹^,² ,
Yuanzhi Chen¹^,² ,
Fentian Chen¹^,² ,
Lin Xu¹^,² ,
Yang Zhao³ ,
Xiaoqing Chen¹^,² ,
Jixian Tang¹^,² ,
Yunlong Ren¹^,² ,
Xiaowen Yan³^,⁴ ,
Wenxin Luo¹^,² ,
Ningshao Xia¹^,²

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Xue Liu, Wenjing Ning, Lei Wang, Han Liu, Hongye Zeng, Xiaojing Qin, Yuanzhi Chen, Fentian Chen, Lin Xu, Yang Zhao, Xiaoqing Chen, Jixian Tang, Yunlong Ren, Xiaowen Yan, Wenxin Luo, Ningshao Xia. Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill. Cancer Communications, 2024, 44(12): 1444‒1448 https://doi.org/10.1002/cac2.12616

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023; 22(8): 641–661. CrossRef Google scholar

[2]	Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023; 20(8): 558–576. CrossRef Google scholar

[3]	Passaro A, Jänne PA, Peters S. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. J Clin Oncol. 2023; 41(21): 3747–3761. CrossRef Google scholar

[4]	Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024; 21(3): 203–223. CrossRef Google scholar

[5]	Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8): 583–592. CrossRef Google scholar

[6]	Strack R. Nanobodies made versatile. Nat Methods. 2023; 20(1): 37. CrossRef Google scholar

[7]	Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82: 775–797. CrossRef Google scholar

[8]	Wu Y, Li Q, Kong Y, Wang Z, Lei C, Li j, et al. A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Mol Ther. 2022; 30(8): 2785–2799. CrossRef Google scholar

[9]	Gan X, Shan Q, Li H, Janssens R, Shen Y, He Y, et al. An anti-CTLA-4 heavy chain-only antibody with enhanced Treg depletion shows excellent preclinical efficacy and safety profile. Proc Natl Acad Sci U S A. 2022; 119(32): e2200879119. CrossRef Google scholar

[10]	Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, et al. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnology. 2023; 21(1): 410. CrossRef Google scholar